Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 23Prostatic Neoplasms 9Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 3Fibrosis 3Carcinoma, Intraductal, Noninfiltrating 3Ovarian Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphedema 2Liver Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Anatomic Stage I Breast Cancer AJCC v8 2Wilms Tumor 1Uterine Hemorrhage 1Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Nodule 1Thyroid Cancer, Papillary 1Stomatitis 1Stomach Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Somatostatinoma 1Sarcoma, Endometrial Stromal 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Pheochromocytoma 1Pain 1Oropharyngeal Neoplasms 1

Interventions

pembrolizumab 162Carboplatin 144Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 38Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × High-Energy Shock Waves × Clear all
NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

University of Southern California

Phase 1 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

M.D. Anderson Cancer Center

Phase NA Active not recruiting
798 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡